1
|
Li J, Guo H, Dong Y, Yuan S, Wei X, Zhang Y, Dong L, Wang F, Bai T, Yang Y. Polysaccharides from Chinese herbal medicine: a review on the hepatoprotective and molecular mechanism. Chin J Nat Med 2024; 22:4-14. [PMID: 38278558 DOI: 10.1016/s1875-5364(24)60558-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2023] [Indexed: 01/28/2024]
Abstract
Polysaccharides, predominantly extracted from traditional Chinese medicinal herbs such as Lycium barbarum, Angelica sinensis, Astragalus membranaceus, Dendrobium officinale, Ganoderma lucidum, and Poria cocos, represent principal bioactive constituents extensively utilized in Chinese medicine. These compounds have demonstrated significant anti-inflammatory capabilities, especially anti-liver injury activities, while exhibiting minimal adverse effects. This review summarized recent studies to elucidate the hepatoprotective efficacy and underlying molecular mechanisms of these herbal polysaccharides. It underscored the role of these polysaccharides in regulating hepatic function, enhancing immunological responses, and improving antioxidant capacities, thus contributing to the attenuation of hepatocyte apoptosis and liver protection. Analyses of molecular pathways in these studies revealed the intricate and indispensable functions of traditional Chinese herbal polysaccharides in liver injury management. Therefore, this review provides a thorough examination of the hepatoprotective attributes and molecular mechanisms of these medicinal polysaccharides, thereby offering valuable insights for the advancement of polysaccharide-based therapeutic research and their potential clinical applications in liver disease treatment.
Collapse
Affiliation(s)
- Jifeng Li
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Haolin Guo
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Ying Dong
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Shuo Yuan
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji 133002, China
| | - Xiaotong Wei
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Yuxin Zhang
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Lu Dong
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Fei Wang
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China
| | - Ting Bai
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China.
| | - Yong Yang
- Dalian Key Laboratory of Chronic Disease Research Center, Dalian University, Dalian 116622, China.
| |
Collapse
|
2
|
Geographical and Temporal Variation in the Incidence and Mortality of Hepato-Pancreato-Biliary Primary Malignancies:1990-2017. J Surg Res 2019; 245:89-98. [PMID: 31404895 DOI: 10.1016/j.jss.2019.07.031] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2019] [Revised: 04/25/2019] [Accepted: 07/12/2019] [Indexed: 12/12/2022]
Abstract
BACKGROUND Hepatic, pancreas, and biliary (HPB) cancers pose serious challenges to global health care systems. These malignancies demonstrate great geographical variations with shifting trends over time. The aim of the present study was to determine the recent trends in incidence, prevalence, and mortality of primary HPB malignancies to guide the further development of effective strategies for prevention, screening, and treatment. METHODS The Global Burden of Disease (GBD) dataset 1990-2017 was interrogated for end point variables by age, sex, year, and geography. Epidemiologic data were modeled in DisMod-MR 2.1, a Bayesian meta-regression tool that pools data points from different sources and adjusts for known sources of variability. Global Burden of Disease data were extracted from 284 country-year, and 976 subnational-year combinations from 27 countries in North America, Latin America, Europe, India, and New Zealand. RESULTS Although the global incidence of primary HPB malignancies increased by 1.43% from 1990 to 2017 (1,400,739 cases), the incidence of extrahepatic biliary and gallbladder malignancies decreased by -0.32% (210,878 cases) over the same period. There was significant variability in the incidence, prevalence, and mortality of HPB cancers by the sociodemographic index (SDI), as well as by geography. The largest incidence increase of primary liver and pancreas cancers was seen in the high-income Asia-Pacific group, followed by the high-income North America and Western Europe groups. The highest incidences and prevalence of extrahepatic biliary and gallbladder malignancies were observed in Asia-Pacific, Southern Latin American, and Andean Latin American regions. In general, mortality rates of HPB malignancies were larger in the low SDI when compared with the high SDI group in all geographical regions. CONCLUSIONS The global incidence and prevalence of primary liver and pancreatic malignancies continue to increase with great geographical variation. The mortality trends mirror those of the incidence. Although the global incidence and prevalence of extrahepatic biliary and gallbladder malignancies has decreased, the mortality rate has not significantly changed. The results of this article can assist local and regional authorities in policy development to improve health care access for screening, early detection, and treatment of HPB malignancies.
Collapse
|
3
|
Wang KF, Chen YD, Mo LQ, Zhang Z, Liu YJ, Chen JX, Sui XB, Xie T, Wu SX. Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. Shijie Huaren Xiaohua Zazhi 2019; 27:459-466. [DOI: 10.11569/wcjd.v27.i7.459] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
As the branches of oncology become more and more detailed, its deficiencies gradually appear in clinical work in recent years. With the development of modern medicine, individualized treatment of hepatocellular carcinoma (HCC) has already been more emphasized in clinical work. This article reviews the diagnosis and treatment of HCC, which can be regarded as an organic systemic disease, based on a concept of integrated medicine. It is suggested that simply eliminating cancer lesions does not mean curing HCC. In clinical practice, it is necessary to use integrative thoughts such as basic study combined with clinical practice, medicine with pharmacy, traditional Chinese medicine with Western medicine, local with whole, etc, so as to find new integrative methods for diagnosis and treatment of HCC.
Collapse
Affiliation(s)
- Kai-Feng Wang
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| | - Yi-Dan Chen
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| | - Li-Qin Mo
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| | - Zhen Zhang
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| | - Ya-Juan Liu
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| | - Jiang-Xiang Chen
- Institute of Integrative Medicine, Hangzhou Normal University, Hangzhou 310002, Zhejiang Province, China
| | - Xin-Bing Sui
- Institute of Integrative Medicine, Hangzhou Normal University, Hangzhou 310002, Zhejiang Province, China
| | - Tian Xie
- Institute of Integrative Medicine, Hangzhou Normal University, Hangzhou 310002, Zhejiang Province, China
| | - Shi-Xiu Wu
- Department of Abdominal Oncology, Hangzhou Cancer Hospital, Hangzhou 310002, Zhejiang Province, China
| |
Collapse
|
4
|
Wang L, Min Z, Wang X, Hu M, Song D, Ren Z, Cheng Y, Wang Y. Arsenic trioxide and sorafenib combination therapy for human hepatocellular carcinoma functions via up-regulation of TNF-related apoptosis-inducing ligand. Oncol Lett 2018; 16:3341-3350. [PMID: 30127933 DOI: 10.3892/ol.2018.8981] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 04/27/2018] [Indexed: 12/18/2022] Open
Abstract
The survival benefits of sorafenib treatment for patients with hepatocellular carcinoma (HCC) are limited due to drug resistance and side effects. Therefore, combinations of sorafenib with other low toxicity drugs, including arsenic trioxide (As2O3) require investigation. The present study aimed to evaluate the potency of apoptosis-induction by As2O3/sorafenib treatment in HCC cell lines, Huh7, 97H and freshly-isolated HCC cells, and also to elucidate the underlying mechanism. A total of 10 patients with HCC were enrolled in the present study. Freshly-isolated HCC cells were purified from HCC tissues collected at surgery. HCC-cell apoptosis was measured by flow cytometry using proprium iodide/Annexin-V staining. The impacts of As2O3 and/or sorafenib on Huh7, 97H and fresh-isolated HCC-cell proliferation were evaluated by Cell Counting Kit-8 assay. The expression of TNF-related apoptosis-inducing ligand (TRAIL) was determined by reverse transcription-quantitative polymerase chain reaction and western blotting. The downregulation of TRAIL protein expression was achieved using small interfering RNA. The combination of As2O3 and sorafenib had anti-proliferative and pro-apoptotic effects in the liver cancer cell line, Huh7, via increased expression of TRAIL, but not in 97H cells. TRAIL-knockdown increased the drug-resistance of Huh7 cells. Freshly-isolated HCC cells were more sensitive to the As2O3 and sorafenib combination than the single drug treatments. Overall, the combination of As2O3 and sorafenib demonstrated potent anti-tumor activity in Huh7 and freshly-isolated HCC cells via a TRAIL-dependent pathway. This may be a potential therapeutic approach for advanced HCC treatment.
Collapse
Affiliation(s)
- Lingyan Wang
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Shanghai Institute of Clinical Bioinformatics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Zhihui Min
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Shanghai Institute of Clinical Bioinformatics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Xiangdong Wang
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Shanghai Institute of Clinical Bioinformatics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Mushuang Hu
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Dongli Song
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Shanghai Institute of Clinical Bioinformatics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Zhenggang Ren
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| | - Yunfeng Cheng
- Institute of Clinical Science, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Shanghai Institute of Clinical Bioinformatics, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.,Department of Hematology, Zhongshan Hospital Qingpu Branch, Shanghai 201700, P.R. China
| | - Yanhong Wang
- Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China
| |
Collapse
|
5
|
Ding K, Fan L, Chen S, Wang Y, Yu H, Sun Y, Yu J, Wang L, Liu X, Liu Y. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep 2015; 34:3297-303. [PMID: 26397192 DOI: 10.3892/or.2015.4306] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 07/13/2015] [Indexed: 11/06/2022] Open
Abstract
Osteopontin (OPN) is a multi-functional cytokine involved in cell survival, migration and adhesion. Increasing evidence has elucidated its role in tumorigenesis, progression and metastasis. However, the role of OPN in chemoresistance of human hepatocellular carcinoma (HCC) has not yet been clarified. In the present study, we examined the expression of OPN in human HCC samples before and after cisplatin-treatment, the results showed that OPN was significantly increased in cisplatin-resistant specimens. We then studied the effect of cisplatin on OPN expression in HCC cells, after exposure to cisplatin, the expression of OPN in HCC cells was elevated compared to control cells. We also found that PI3K/AKT signaling pathway was also activated by cisplatin and this effect was induced by the OPN pathway. To study the effect of OPN on chemoresistance, HCC cells were treated with cisplatin along with OPN. Incubation with OPN enchanced the chemoresistance of HCC cells to cisplatin. In contrast, blockage of OPN pathway promoted the chemosensitivity of HCC cells to cisplatin. Our results suggest that OPN enhanced chemoresistance of cisplatin in HCC cells by activating PI3K/AKT signaling pathway, blocking the OPN pathway might be a novel way to overcome the disease.
Collapse
Affiliation(s)
- Kun Ding
- Department of Liver Diseases, Jinan Infectious Disease Hospital, Shandong University School of Medicine, Jian, Shandong 250000, P.R. China
| | - Lu Fan
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Shijun Chen
- Department of Liver Diseases, Jinan Infectious Disease Hospital, Shandong University School of Medicine, Jian, Shandong 250000, P.R. China
| | - Yanna Wang
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Haifeng Yu
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Yanni Sun
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Jiguang Yu
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Li Wang
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Xiangzhong Liu
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| | - Youde Liu
- Yantai Infectious Disease Hospital, Yantai, Shandong 264001, P.R. China
| |
Collapse
|
6
|
Gonzales JF, Barnard ND, Jenkins DJA, Lanou AJ, Davis B, Saxe G, Levin S. Applying the precautionary principle to nutrition and cancer. J Am Coll Nutr 2014; 33:239-46. [PMID: 24870117 DOI: 10.1080/07315724.2013.866527] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
PRIMARY OBJECTIVE Research has identified certain foods and dietary patterns that are associated with reduced cancer risk and improved survival after cancer diagnosis. This research has formed the basis for dietary guidance issued by cancer organizations. Unfortunately, gaps within nutrition research have made it difficult to make recommendations in some areas. This review specifies suggested dietary guidance in which evidence of a dietary influence on cancer risk is substantial, even if not conclusive. Evidence summaries within the review are based on the 2007 report of the World Cancer Research Fund/American Institute for Cancer Research. This review also describes advantages and disadvantages of following the suggested dietary guidance and includes putative mechanisms involved in cancer progression. MAIN OUTCOMES AND RESULTS Suggested dietary guidance where evidence is sufficiently compelling include (1) limiting or avoiding dairy products to reduce the risk of prostate cancer; (2) limiting or avoiding alcohol to reduce the risk of cancers of the mouth, pharynx, larynx, esophagus, colon, rectum, and breast; (3) avoiding red and processed meat to reduce the risk of cancers of the colon and rectum; (4) avoiding grilled, fried, and broiled meats to reduce the risk of cancers of the colon, rectum, breast, prostate, kidney, and pancreas; (5) consumption of soy products during adolescence to reduce the risk of breast cancer in adulthood and to reduce the risk of recurrence and mortality for women previously treated for breast cancer; and (6) emphasizing fruits and vegetables to reduce risk of several common forms of cancer. CONCLUSION By adopting the precautionary principle for nutrition research, this review aims to serve as a useful tool for practitioners and patients.
Collapse
Affiliation(s)
- Joseph F Gonzales
- a Physicians Committee for Responsible Medicine, Clinical Research , Washington , D.C
| | | | | | | | | | | | | |
Collapse
|
7
|
Abou El Azm AR, Yousef M, Mansour N, Awad A, El Dardiry S, Abdel Aziz I. New Insights on Non-B non-C Hepatocellular Carcinoma in Mid Delta Region, Egypt. J Gastrointest Cancer 2014; 45:276-83. [DOI: 10.1007/s12029-013-9573-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
8
|
El Azm ARA, Yousef M, Salah R, Mayah W, Tawfeek S, Ghorabah H, Mansour N. Serum anti-P53 antibodies and alpha-fetoprotein in patients with non-B non-C hepatocellular carcinoma. SPRINGERPLUS 2013; 2:69. [PMID: 23518665 PMCID: PMC3601255 DOI: 10.1186/2193-1801-2-69] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2012] [Accepted: 02/04/2013] [Indexed: 01/21/2023]
Abstract
The rate of hepatocellular carcinoma (HCC) is increasing worldwide including Egypt. Non-B non-C HCC was reported in some countries. We aimed to investigate P53 antibodies and alpha-fetoprotein in patients with non-B non-C HCC in our region. In a case series study, included 281 patients with HCC and 20 patients with liver cirrhosis of matched age, sex and social factors were received for management at Tanta University Hospitals. Sera were tested for HCV and HBV markers by ELISA/PCR, alpha-fetoprotein (AFP) level and anti-p53 antibody were evaluated by ELISA. Antinuclear antibody, serum copper and iron were assessed in non-viral HCC. Liver scanning and biopsy were evaluated. Non-B non-C HCC patients were 13.87% of total. P53 antibody serum level in non-B non-C HCC patients showed insignificant difference (p>0.05) as compared to viral-associated HCC, while significant as compared to cirrhosis. They had significant decrease in serum AFP level (p<0.001) as compared to viral-associated HCC. Their tumors were mainly solitary, and have smaller-sizes. Sensitivity, specificity, PPV, NPV and accuracy test of anti P53 antibody positive patients were 91.52%, 84.63%, 90.34%, 80.2% and 74.8% respectively. It correlates positively with AFP, tumor size and staging, MELD score and Child-Pugh score. Non-B non-C HCC showed high serum prevalence of anti-p53 as viral-associated HCC suggesting an evidence of high onchogenecity. It appears of much benefit in diagnosis, follow up and differentiation from cirrhosis in presence of low levels of alpha-fetoprotein.
Collapse
Affiliation(s)
- Abdel Raouf Abou El Azm
- Faculty of Medicine, Egypt and president of the Egyptian Society of Liver and Environment, Tanta University, Tanta, Egypt
| | | | | | | | | | | | | |
Collapse
|